Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: Randomized placebo-controlled trial

Bizino, Maurice B.; Jazet, Ingrid M.; Westenberg, Jos J. M.; van Eyk, Huub J.; Paiman, Elisabeth H. M.; Smit, Jan W. A.; Lamb, Hildebrandus J.

doi:10.1186/s12933-019-0857-6

Cited by 137Diabetes Treatment and ManagementCardiovascular Function and Risk FactorsHeart Failure Treatment and Management

Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: Randomized placebo-controlled trial

Open access

Bizino, Maurice B., Jazet, Ingrid M., Westenberg, Jos J. M., van Eyk, Huub J., Paiman, Elisabeth H. M., Smit, Jan W. A., Lamb, Hildebrandus J.·2019·Cardiovascular Diabetology

DOI 10.1186/s12933-019-0857-6PMC PMC6492440

Open this paper in CoChat — free account Open PDF

Abstract

Abstract Background Liraglutide is an antidiabetic agent with cardioprotective effect. The purpose of this study is to test efficacy of liraglutide to improve diabetic cardiomyopathy in patients with diabetes mellitus type 2 (DM2) without cardiovascular disease. Methods Patients with DM2 were randomly assigned to receive liraglutide 1.8 mg/day or placebo in this double-blind trial of 26 weeks. Primary outcome measures were LV diastolic function (early (E) and late (A) transmitral peak flow rate, E/A ratio, early deceleration peak (Edec), early peak mitral annular septal tissue velocity (Ea) and estimated LV filling pressure (E/Ea), and systolic function (stroke volume, ejection fraction, cardiac output, cardiac index and peak ejection rate) assessed with CMR. Intention-to-treat analysis of between-group differences was performed using ANCOVA. Mean estimated treatment differences (95% confidence intervals) are reported. Results 23 patients were randomized to liraglutide and 26 to placebo. As compared with placebo, liraglutide significantly reduced E (− 56 mL/s (− 91 to − 21)), E/A ratio (− 0.17 (− 0.27 to − 0.06)), Edec (− 0.9 mL/s 2 * 10 −3 (− 1.3 to − 0.2)) and E/Ea (− 1.8 (− 3.0 to − 0.6)), without affecting A (3 mL/s (− 35 to 41)) and Ea (0.4 cm/s (− 0.9 to 1.4)). Liraglutide reduced stroke volume (− 9 mL (− 16 to − 2)) and ejection fraction (− 3% (− 6 to − 0.1)), but did not change cardiac output (− 0.4 L/min (− 0.9 to 0.2)), cardiac index (− 0.1 L/min/m 2 (− 0.4 to 0.1)) and peak ejection rate (− 46 mL/s (− 95 to 3)). Conclusions Liraglutide reduced early LV diastolic filling and LV filling pressure, thereby unloading the left ventricle. LV systolic function reduced and remained within normal range. Future studies are needed to investigate if liraglutide-induced left ventricular unloading slows progression of diabetic cardiomyopathy into symptomatic stages. Trial registration ClinicalTrials.gov: NCT01761318.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1186/s12933-019-0857-6

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Liraglutide reduces LV filling pressure and improves diastolic function, parameters relevant for progression of diabetic cardiomyopathy and symptomatic HFpEF.
“Among these, a study with liraglutide demonstrated a reduction in LV filling pressure and an improvement in diastolic function, both parameters relevant for progression of diabetic cardiomyopathy and symptomatic HFpEF [171].”
From Dysregulated epicardial adipose tissue as a risk factor and potential therapeutic target of heart failure with preserved ejection fraction in diabetes (2022) · cites this paper as [171]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536 · see citing works
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · see citing works
Burden of Systolic and Diastolic Ventricular Dysfunction in the Community
Redfield, M. M., Jacobsen, S. J., Burnett, J. C. J., Mahoney, D. W., Bailey, K. R., & Rodeheffer, R. J. (2003) · JAMA · doi:10.1001/jama.289.2.194 · Cited by 2,989 · see citing works
Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial
Margulies, K. B., Hernandez, A. F., Redfield, M. M., Givertz, M. M., Oliveira, G. H., Cole, R., Mann, D. L., Whellan, D. J., Kiernan, M. S., Felker, G. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.10260 · Cited by 706 · see citing works
Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme
MacDonald, M. R., Petrie, M. C., Varyani, F., Ostergren, J., Michelson, E. L., Young, J. B., Solomon, S. D., Granger, C. B., Swedberg, K., Yusuf, S., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn153 · Cited by 694 · see citing works
Glucagon-Like Peptide-1 Infusion Improves Left Ventricular Ejection Fraction and Functional Status in Patients With Chronic Heart Failure
Sokos, G. G., Nikolaidis, L. A., Mankad, S. V., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 654 · see citing works
Reference ranges for cardiac structure and function using cardiovascular magnetic resonance (CMR) in Caucasians from the UK Biobank population cohort
Petersen, S. E., Aung, N., Sanghvi, M. M., Zemrak, F., Fung, K., Paiva, J. M., Francis, J. M., Khanji, M. Y., Lukaschuk, E. I., Lee, A. M., et al. (2016) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/s12968-017-0327-9 · Cited by 601 · see citing works
Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double-blind, randomised, placebo-controlled trial
Jorsal, A., Kistorp, C., Holmager, P., Tougaard, R. S., Nielsen, R., Hänselmann, A., Nilsson, B., Møller, J. E., Hjort, J., Rasmussen, J., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.657 · Cited by 592 · see citing works
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582 · see citing works
The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE−/− and LDLr−/− Mice by a Mechanism That Includes Inflammatory Pathways
Rakipovski, G., Rolin, B., Nøhr, J., Klewe, I., Frederiksen, K. S., Augustin, R., Hecksher-Sørensen, J., Ingvorsen, C., Polex-Wolf, J., & Knudsen, L. B. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.09.004 · Cited by 509 · see citing works
Effect of Obesity and Overweight on Left Ventricular Diastolic Function
Russo, C., Jin, Z., Homma, S., Rundek, T., Elkind, M. S. V., Sacco, R. L., & Di Tullio, M. R. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.10.042 · Cited by 361 · see citing works
Cardiovascular Actions of Incretin-Based Therapies
Ussher, J. R., & Drucker, D. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.301958 · Cited by 358 · see citing works
The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the strong heart study
Liu, J. E., Palmieri, V., Roman, M. J., Bella, J., Fabsitz, R. R., Howard, B. V., Welty, T. K., Lee, E. T., & Devereux, R. B. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01230-x · Cited by 350 · see citing works
GLP-1 Receptor Expression Within the Human Heart
Baggio, L. L., Yusta, B., Mulvihill, E. E., Cao, X., Streutker, C. J., Butany, J., Cappola, T. P., Margulies, K. B., & Drucker, D. J. (2018) · Endocrinology · doi:10.1210/en.2018-00004 · Cited by 312 · see citing works
Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored
McMurray, J. J. V., Gerstein, H. C., Holman, R. R., & Pfeffer, M. A. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70031-2 · Cited by 303 · see citing works
Prolonged Caloric Restriction in Obese Patients With Type 2 Diabetes Mellitus Decreases Myocardial Triglyceride Content and Improves Myocardial Function
Hammer, S., Snel, M., Lamb, H. J., Jazet, I. M., van der Meer, R. W., Pijl, H., Meinders, E. A., Romijn, J. A., Roos, A., & Smit, J. W. A. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.04.068 · Cited by 264 · see citing works
Pioglitazone Improves Cardiac Function and Alters Myocardial Substrate Metabolism Without Affecting Cardiac Triglyceride Accumulation and High-Energy Phosphate Metabolism in Patients With Well-Controlled Type 2 Diabetes Mellitus
van der Meer, R. W., Rijzewijk, L. J., de Jong, H. W. A. M., Lamb, H. J., Lubberink, M., Romijn, J. A., Bax, J. J., Roos, A., Otto Kamp, B., Paulus, W. J., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.803916 · Cited by 234 · see citing works
Cardiovascular Phenotype in HFpEF Patients With or Without Diabetes
Lindman, B. R., Dávila-Román, V. G., Mann, D. L., McNulty, S., Semigran, M. J., Lewis, G. D., de las Fuentes, L., Joseph, S. M., Vader, J., Hernandez, A. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.05.030 · Cited by 209 · see citing works
Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans
Koska, J., Sands, M., Burciu, C., D’Souza, K. M., Raravikar, K., Liu, J., Truran, S., Franco, D. A., Schwartz, E. A., Schwenke, D. C., et al. (2015) · Diabetes · doi:10.2337/db14-0976 · Cited by 174 · see citing works
Feasibility of tissue magnetic resonance imaging
Paelinck, B. P., Roos, A., Bax, J. J., Bosmans, J. M., van der Geest, R. J., Dhondt, D., Parizel, P. M., Vrints, C. J., & Lamb, H. J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.12.051 · Cited by 152 · see citing works
Changes in Diastolic Dysfunction in Diabetes Mellitus Over Time
From, A. M., Scott, C. G., & Chen, H. H. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.01.358 · Cited by 152 · see citing works
Association of albuminuria with systolic and diastolic left ventricular dysfunction in type 2 diabetes
Liu, J. E., Robbins, D. C., Palmieri, V., Bella, J. N., Roman, M. J., Fabsitz, R. R., Howard, B. V., Welty, T. K., Lee, E. T., & Devereux, R. B. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00403-0 · Cited by 149 · see citing works
Effect of Selective Heart Rate Slowing in Heart Failure With Preserved Ejection Fraction
Pal, N., Sivaswamy, N., Mahmod, M., Yavari, A., Rudd, A. E., Singh, S., Dawson, D. K., Francis, J. M., Dwight, J. S., Watkins, H. C., et al. (2015) · Circulation · doi:10.1161/circulationaha.115.017119 · Cited by 148 · see citing works
Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes
Lambadiari, V., Pavlidis, G., Kousathana, F., Varoudi, M., Vlastos, D., Maratou, E., Georgiou, D., Andreadou, I., Parissis, J., Triantafyllidi, H., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0646-z · Cited by 146 · see citing works
Short‐term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial
Skov, J., Pedersen, M., Holst, J. J., Madsen, B., Goetze, J. P., Rittig, S., Jonassen, T., Frøkiær, J., Dejgaard, A., & Christiansen, J. S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12651 · Cited by 128 · see citing works
Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: A pre-specified secondary study on ectopic fat accumulation
Bizino, M. B., Jazet, I. M., de Heer, P., van Eyk, H. J., Dekkers, I. A., Rensen, P. C. N., Paiman, E. H. M., Lamb, H. J., & Smit, J. W. (2020) · Diabetologia · doi:10.1007/s00125-019-05021-6 · Cited by 123 · see citing works
Self-citation
Preclinical Systolic and Diastolic Dysfunctions in Metabolically Healthy and Unhealthy Obese Individuals
Wang, Y., Liang, C., Gopal, D. M., Ayalon, N., Donohue, C., Santhanakrishnan, R., Sandhu, H., Perez, A. J., Downing, J., Gokce, N., et al. (2015) · Circulation Heart Failure · doi:10.1161/circheartfailure.114.002026 · Cited by 90 · see citing works
Heart failure preserved ejection fraction (HFpEF): an integrated and strategic review
Lekavich, C. L., Barksdale, D. J., Neelon, V. J., & Wu, J. R. (2015) · Heart Failure Reviews · doi:10.1007/s10741-015-9506-7 · Cited by 88 · see citing works
Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis
Bruen, R., Curley, S., Kajani, S., Crean, D., O'Reilly, M. E., Lucitt, M. B., Godson, C., McGillicuddy, F. C., & Belton, O. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0626-3 · Cited by 81 · see citing works
A Randomized Trial of the Impact of Strict Glycaemic Control on Myocardial Diastolic Function and Perfusion Reserve: A Report from the DADD (Diabetes Mellitus and Diastolic Dysfunction) Study
Jarnert, C., Landstedt‐Hallin, L., Malmberg, K., Melcher, A., Öhrvik, J., Persson, H., & Rydén, L. (2009) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfn018 · Cited by 74 · see citing works
CMR for Assessment of Diastolic Function
Westenberg, J. J. M. (2011) · Current Cardiovascular Imaging Reports · doi:10.1007/s12410-011-9070-z · Cited by 65 · see citing works
Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis
Zhang, D.-P., Xu, L., Wang, L., Wang, H.-J., & Jiang, F. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-0987-x · Cited by 64 · see citing works
Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice
Longato, E., Camillo, B. D., Sparacino, G., Tramontan, L., Avogaro, A., & Fadini, G. P. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01049-w · Cited by 58 · see citing works
Left ventricular diastolic function assessment from three‐dimensional three‐directional velocity‐encoded MRI with retrospective valve tracking
Brandts, A., Bertini, M., van Dijk, E., Delgado, V., Marsan, N. A., van der Geest, R. J., Siebelink, H. J., Roos, A., Bax, J. J., & Westenberg, J. J. M. (2011) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.22424 · Cited by 57 · see citing works
The role of endothelial nitric oxide in the anti-restenotic effects of liraglutide in a mouse model of restenosis
Kushima, H., Mori, Y., Koshibu, M., Hiromura, M., Kohashi, K., Terasaki, M., Fukui, T., & Hirano, T. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0603-x · Cited by 48 · see citing works
Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study
Yang, C., Yang, C., Ou, H., & Kuo, S. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01053-0 · Cited by 48 · see citing works
Effect of Liraglutide on Cardiovascular Function and Myocardial Tissue Characteristics in Type 2 Diabetes Patients of South Asian Descent Living in the Netherlands: A Double‐Blind, Randomized, Placebo‐Controlled Trial
Paiman, E. H. M., van Eyk, H. J., van Aalst, M., Bizino, M. B., van der Geest, R. J., Westenberg, J. J. M., Geelhoed-Duijvestijn, P. H. L. M., Kharagjitsingh, A. V., Rensen, P. C. N., Smit, J. W. A., et al. (2019) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.27009 · Cited by 42 · see citing works
Improved diastolic function in type 2 diabetes after a six month liraglutide treatment
Saponaro, F., Sonaglioni, A., Rossi, A., Montefusco, L., Lombardo, M., Adda, G., & Arosio, M. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.04.046 · Cited by 41 · see citing works
Influence of sympathetic stimulation and parasympathetic withdrawal on Doppler echocardiographic left ventricular diastolic filling velocities in young normal subjects
Johannessen, K.-A., Cerqueira, M. D., Veith, R. C., & Stratton, J. R. (1991) · The American Journal of Cardiology · doi:10.1016/0002-9149(91)90015-d · Cited by 40 · see citing works
Effect of exercise combined with glucagon‐like peptide‐1 receptor agonist treatment on cardiac function: A randomized double‐blind placebo‐controlled clinical trial
Jørgensen, P. G., Jensen, M. T., Mensberg, P., Storgaard, H., Nyby, S., Jensen, J. S., Knop, F. K., & Vilsbøll, T. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12900 · Cited by 36 · see citing works
Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment vs. Glimepiride Both in Combination with Metformin: A Randomized Open Parallel-Group Study
Nyström, T., Santos‐Pardo, I., Hedberg, F., Wardell, J., Witt, N., Cao, Y., Bojö, L., Nilsson, B., & JENDLE, J. H. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00325 · Cited by 26 · see citing works
High spatial resolution free-breathing 3D late gadolinium enhancement cardiac magnetic resonance imaging in ischaemic and non-ischaemic cardiomyopathy: quantitative assessment of scar mass and image quality
Bizino, M. B., Tao, Q., Amersfoort, J., Siebelink, H. J., Boogaard, P. J. V. D., van der Geest, R. J., & Lamb, H. J. (2018) · European Radiology · doi:10.1007/s00330-018-5361-y · Cited by 25 · see citing works

Flagged first, then by citations

Sorted by citations

Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence
Tan, Y., Zhang, Z., Zheng, C., Wintergerst, K. A., Keller, B. B., & Cai, L. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0339-2 · Cited by 846 · see citing works
The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction
Withaar, C., Meems, L. M. G., Markousis-Mavrogenis, G., Boogerd, C. J., Silljé, H. H. W., Schouten, E. M., Dokter, M. M., Voors, A. A., Westenbrink, B. D., Lam, C. S. P., et al. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa256 · Cited by 223 · see citing works
Autophagy in the diabetic heart: A potential pharmacotherapeutic target in diabetic cardiomyopathy
Dewanjee, S., Vallamkondu, J., Kalra, R. S., John, A. A., Reddy, P. H., & Kandimalla, R. J. L. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101338 · Cited by 174 · see citing works
Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization
Khan, M. S., Fonarow, G. C., McGuire, D. K., Hernandez, A. F., Vaduganathan, M., Rosenstock, J., Handelsman, Y., Verma, S., Anker, S. D., McMurray, J. J. V., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.045888 · Cited by 139 · see citing works
Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: A pre-specified secondary study on ectopic fat accumulation
Bizino, M. B., Jazet, I. M., de Heer, P., van Eyk, H. J., Dekkers, I. A., Rensen, P. C. N., Paiman, E. H. M., Lamb, H. J., & Smit, J. W. (2020) · Diabetologia · doi:10.1007/s00125-019-05021-6 · Cited by 123 · see citing works
Self-citation
Diabetic cardiomyopathy: Clinical phenotype and practice
Zhao, X., Liu, S., Wang, X., Chen, Y., Pang, P., Yang, Q., Lin, J., Deng, S., Shen-tao, W., Fan, G., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1032268 · Cited by 122 · see citing works
Relationship of Nonalcoholic Fatty Liver Disease and Heart Failure With Preserved Ejection Fraction
Salah, H. M., Pandey, A., Soloveva, A. E., Abdelmalek, M. F., Diehl, A. M., Moylan, C. A., Wegermann, K., Rao, V. N., Hernandez, A. F., Tedford, R. J., et al. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.07.010 · Cited by 106 · see citing works
A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients
van Eyk, H. J., Paiman, E. H. M., Bizino, M. B., de Heer, P., Geelhoed-Duijvestijn, P. H., Kharagjitsingh, A. V., Smit, J. W. A., Lamb, H. J., Rensen, P. C. N., & Jazet, I. M. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0890-5 · Cited by 90 · see citing works
The cardioprotective effects of semaglutide exceed those of dietary weight loss in mice with HFpEF
Withaar, C., Meems, L. M. G., Nollet, E. E., Schouten, E. M., Schroeder, M. A., Knudsen, L. B., Niss, K., Madsen, C. T., Hoegl, A., Mazzoni, G., et al. (2023) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2023.05.012 · Cited by 74 · see citing works
GLP-1 receptor agonist liraglutide protects cardiomyocytes from IL-1β-induced metabolic disturbance and mitochondrial dysfunction
Zhang, L., Tian, J., Diao, S., Zhang, G., Xiao, M., & Chang, D. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.109252 · Cited by 73 · see citing works
Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence
Natali, A., Nesti, L., Tricò, D., & Ferrannini, E. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01385-5 · Cited by 70 · see citing works
A comprehensive survey on low-cost ECG acquisition systems: Advances on design specifications, challenges and future direction
Faruk, N., Abdulkarim, A., Emmanuel, I., Folawiyo, Y. Y., Adewole, K. S., Mojeed, H. A., Oloyede, A. A., Olawoyin, L. A., Sikiru, I. A., Nehemiah, M., et al. (2021) · Journal of Applied Biomedicine · doi:10.1016/j.bbe.2021.02.007 · Cited by 65 · see citing works
Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis
Zhang, D.-P., Xu, L., Wang, L., Wang, H.-J., & Jiang, F. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-0987-x · Cited by 64 · see citing works
Dysregulated epicardial adipose tissue as a risk factor and potential therapeutic target of heart failure with preserved ejection fraction in diabetes
Salvatore, T., Galiero, R., Caturano, A., Vetrano, E., Rinaldi, L., Coviello, F., Di Martino, A., Albanese, G., Colantuoni, S., Medicamento, G., et al. (2022) · Biomolecules · doi:10.3390/biom12020176 · Cited by 62 · see citing works
Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice
Longato, E., Camillo, B. D., Sparacino, G., Tramontan, L., Avogaro, A., & Fadini, G. P. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01049-w · Cited by 58 · see citing works
The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF)
Hullon, D., Subeh, G. K., Volkova, Y., Janiec, K., Trach, A., & Mnevets, R. O. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02607-w · Cited by 58 · see citing works
How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?
Lee, M. M. Y., Petrie, M. C., McMurray, J. J. V., & Sattar, N. A. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.311904 · Cited by 56 · see citing works
Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies
Longo, M., Caruso, P., Maiorino, M. I., Bellastella, G., Giugliano, D., & Esposito, K. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01090-9 · Cited by 54 · see citing works
Epicardial Fat Expansion in Diabetic and Obese Patients with Heart Failure and Preserved Ejection Fraction—A Specific HFpEF Phenotype
Elsanhoury, A., Nelki, V., Kelle, S., Van Linthout, S., & Tschöpe, C. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.720690 · Cited by 51 · see citing works
Cardiovascular Effects of Incretin-Based Therapies: Integrating Mechanisms With Cardiovascular Outcome Trials
Ussher, J. R., Greenwell, A. A., Nguyen, M.-A., & Mulvihill, E. E. (2022) · Diabetes · doi:10.2337/dbi20-0049 · Cited by 51 · see citing works
Cardiovascular Determinants of Aerobic Exercise Capacity in Adults With Type 2 Diabetes
Gulsin, G. S., Henson, J. J., Brady, E. M., Sargeant, J. A., Wilmot, E. G., Athithan, L., Htike, Z. Z., Marsh, A.-M., Biglands, J. D., Kellman, P., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0706 · Cited by 49 · see citing works
Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study
Yang, C., Yang, C., Ou, H., & Kuo, S. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01053-0 · Cited by 48 · see citing works
Distinct non-ischemic myocardial late gadolinium enhancement lesions in patients with type 2 diabetes
Bojer, A. S., Sørensen, M. H., Vejlstrup, N. G., Goetze, J. P., Gæde, P., & Madsen, P. L. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01160-y · Cited by 43 · see citing works
Diabetes and Its Complications: Therapies Available, Anticipated and Aspired
Grover, A., Sharma, K., Gautam, S., Gautam, S., Gulati, M., & Singh, S. K. (2020) · Current Diabetes Reviews · doi:10.2174/1573399816666201103144231 · Cited by 43 · see citing works
Effect of Glucagon-like Peptide-1 Receptor Agonists on Prognosis of Heart Failure and Cardiac Function: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Liu, H., Fu, D., & Daoquan, P. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.12.006 · Cited by 42 · see citing works
Targeting mitochondrial quality control for diabetic cardiomyopathy: Therapeutic potential of hypoglycemic drugs
Zhou, Y., Suo, W., Zhang, X., Liang, J., Zhao, W., Wang, Y., Li, H., & Ni, Q. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115669 · Cited by 42 · see citing works
Effect of Liraglutide on Cardiovascular Function and Myocardial Tissue Characteristics in Type 2 Diabetes Patients of South Asian Descent Living in the Netherlands: A Double‐Blind, Randomized, Placebo‐Controlled Trial
Paiman, E. H. M., van Eyk, H. J., van Aalst, M., Bizino, M. B., van der Geest, R. J., Westenberg, J. J. M., Geelhoed-Duijvestijn, P. H. L. M., Kharagjitsingh, A. V., Rensen, P. C. N., Smit, J. W. A., et al. (2019) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.27009 · Cited by 42 · see citing works
Comparison of Sodium–Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide Receptor Agonists for Atrial Fibrillation in Type 2 Diabetes Mellitus: Systematic Review With Network Meta-analysis of Randomized Controlled Trials
Li, W., Chen, X., Xie, X., Xu, M., Xu, L., Liu, P., & Luo, B. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001197 · Cited by 35 · see citing works
Effect of GLP-1 receptor agonists and co-agonists on atrial fibrillation risk in overweight or obesity: systematic review and meta-analysis of randomized controlled trials
Karakasis, P., Vlachos, K. G., Antoniadis, A. P., Siontis, K. C., Patoulias, D., Fragakis, N., & Mantzoros, C. S. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156463 · Cited by 48 · see citing works
Heart rate variability features from nonlinear cardiac dynamics in identification of diabetes using artificial neural network and support vector machine
Aggarwal, Y., Das, J., Mazumder, P. M., Kumar, R., & Sinha, R. K. (2020) · Journal of Applied Biomedicine · doi:10.1016/j.bbe.2020.05.001 · Cited by 40 · see citing works
Catalpol ameliorates doxorubicin‑induced inflammation and oxidative stress in H9C2 cells through PPAR‑γ activation
Jiang, Y., & Zhang, Q. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8743 · Cited by 36 · see citing works
MOTS-c and Exercise Restore Cardiac Function by Activating of NRG1-ErbB Signaling in Diabetic Rats
Li, S., Wang, M., Ma, J., Pang, X., Yuan, J., Pan, Y., Fu, Y., & Laher, I. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.812032 · Cited by 36 · see citing works
A randomized, open‐label, active comparator trial assessing the effects of 26 weeks of liraglutide or sitagliptin on cardiovascular function in young obese adults with type 2 diabetes
Webb, D. R., Htike, Z. Z., Swarbrick, D. J., Brady, E. M., Gray, L. J., Biglands, J. D., Gulsin, G. S., Henson, J. J., Khunti, K. K., McCann, G. P., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14023 · Cited by 34 · see citing works
Liraglutide Attenuates Myocardial Fibrosis via Inhibition of AT1R-Mediated ROS Production in Hypertensive Mice
Chen, P., Yang, F., Wang, W., Li, X., Liu, D., Zhang, Y., Yin, G., Lv, F., Guo, Z., Mehta, J. L., et al. (2021) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248420942007 · Cited by 31 · see citing works
Ferroptosis in diabetic cardiomyopathy: from its mechanisms to therapeutic strategies
Tian, M., Huang, X., Li, M., Lou, P., Ma, H., Jiang, X., Zhou, Y., & Liu, Y. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1421838 · Cited by 34 · see citing works
GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies
Yang, H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14196758 · Cited by 37 · see citing works
The Impact of Antidiabetic Therapies on Diastolic Dysfunction and Diabetic Cardiomyopathy
Gopal, K., Chahade, J. J., Kim, R., & Ussher, J. R. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.603247 · Cited by 32 · see citing works
Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study
Kumarathurai, P., Sajadieh, A., Anholm, C., Kristiansen, O. P., Haugaard, S. B., & Nielsen, O. W. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01205-2 · Cited by 31 · see citing works
Renal sinus fat volume in type 2 diabetes mellitus is associated with glycated hemoglobin and metabolic risk factors
Lin, L., Dekkers, I. A., Huang, L., Tao, Q., Paiman, E. H. M., Bizino, M. B., Jazet, I. M., & Lamb, H. J. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107973 · Cited by 31 · see citing works
Mitochondrial energy metabolism in diabetic cardiomyopathy: Physiological adaption, pathogenesis, and therapeutic targets
Ye, W., Han, K., Xie, M., Li, S., Chen, G., Wang, Y., & Li, T. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003075 · Cited by 30 · see citing works
Phenotyping diabetic cardiomyopathy in Europeans and South Asians
Paiman, E. H. M., van Eyk, H. J., Bizino, M. B., Dekkers, I. A., de Heer, P., Smit, J. W. A., Jazet, I. M., & Lamb, H. J. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0940-z · Cited by 30 · see citing works
Glycemic Control and the Heart: The Tale of Diabetic Cardiomyopathy Continues
Longo, M., Scappaticcio, L., Cirillo, P., Maio, A., Carotenuto, R. M., Maiorino, M. I., Bellastella, G., & Esposito, K. (2022) · Biomolecules · doi:10.3390/biom12020272 · Cited by 29 · see citing works
Effects of oral antidiabetic drugs and glucagon-like peptide-1 receptor agonists on left ventricular diastolic function in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis
Ida, S., Kaneko, R., Imataka, K., Ôkubo, K., Shirakura, Y., Azuma, K., Fujiwara, R., Takahashi, H., & Murata, K. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-09936-w · Cited by 28 · see citing works
Treatment of HFpEF beyond the SGLT2-Is: Does the Addition of GLP-1 RA Improve Cardiometabolic Risk and Outcomes in Diabetic Patients?
Belli, M., Barone, L., Bellia, A., Sergi, D., Lecis, D., Prandi, F. R., Milite, M., Galluccio, C., Muscoli, S., Romeo, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314598 · Cited by 29 · see citing works
The effect of GLP-1 receptor agonists on N-terminal pro-brain natriuretic peptide. A scoping review and metanalysis
Avogaro, A., Azzolina, D., Gregori, D., de Kreutzenberg, S., Fadini, G. P., & Mannucci, E. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.03.032 · Cited by 27 · see citing works
Effects of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) on Cardiac Structure and Function: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials
Wong, S. Y., Lee, A. R. Y. B., Sia, A. H. J., Wo, Y. J., Teo, Y. H., Teo, Y. N., Syn, N. L. X., Ong, C. C., Teo, L., Yeo, T., et al. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07360-w · Cited by 26 · see citing works
Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension
King, N. E., & Brittain, E. L. (2022) · Pulmonary Circulation · doi:10.1002/pul2.12028 · Cited by 28 · see citing works
Diabesity in Elderly Cardiovascular Disease Patients: Mechanisms and Regulators
García‐Vega, D., González‐Juanatey, J. R., & Eiras-Penas, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147886 · Cited by 25 · see citing works
Glucagon‐like peptide‐1 receptor agonist treatment of high carbohydrate intake‐induced metabolic syndrome provides pleiotropic effects on cardiac dysfunction through alleviations in electrical and intracellular Ca2+ abnormalities and mitochondrial dysfunction
Durak, A. T., Akkuş, E., Canpolat, A. G., Tuncay, E., Çorapçıoğlu, D., & Turan, B. (2021) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13590 · Cited by 23 · see citing works
Diabetes Mellitus and Heart Failure With Preserved Ejection Fraction: Role of Obesity
Dhore-Patil, A., Thannoun, T., Samson, R., & Jemtel, T. H. L. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2021.785879 · Cited by 25 · see citing works
New antidiabetic therapy and HFpEF: light at the end of tunnel?
Tadic, M. V., Sala, C., Saeed, S., Grassi, G. M., Mancia, G., Rottbauer, W., & Cuspidi, C. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10106-9 · Cited by 23 · see citing works
The effect of glucagon‐like peptide‐1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: An updated systematic review and meta‐analysis
Zhang, Y., Yang, D., Jia, Q., Yan, J., & An, F. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15557 · Cited by 22 · see citing works
Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiac Function, Exercise Capacity and Quality of Life
Shchendrygina, A., Rakisheva, A., Giverts, I., Rustamova, Y., & Soloveva, A. E. (2024) · Cardiac failure review · doi:10.15420/cfr.2024.05 · Cited by 21 · see citing works
Pulmonary hypertension associated to left heart disease: Phenotypes and treatment
Madonna, R., Biondi, F., Ghelardoni, S., D'Alleva, A., Quarta, S., & Massaro, M. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.07.030 · Cited by 20 · see citing works
Cardioprotective effects of glucagon-like peptide 1 receptor agonists in heart failure: Myth or truth?
Nesti, L., & Tricò, D. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i5.818 · Cited by 19 · see citing works
Liraglutide in the treatment of heart failure: insight from FIGHT and LIVE
Liang, B., & Gu, N. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01088-3 · Cited by 19 · see citing works
The Effect of Glycemic Control on Renal Triglyceride Content Assessed by Proton Spectroscopy in Patients With Type 2 Diabetes Mellitus: A Single-Center Parallel-Group Trial
Dekkers, I. A., Bizino, M. B., Paiman, E. H. M., Smit, J. W. A., Jazet, I. M., de Vries, A. P. J., & Lamb, H. J. (2020) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2020.09.006 · Cited by 19 · see citing works
Effects of liraglutide vs. lifestyle changes on soluble suppression of tumorigenesis-2 (sST2) and galectin-3 in obese subjects with prediabetes or type 2 diabetes after comparable weight loss
Simeone, P., Tripaldi, R., Michelsen, A. E., Ueland, T., Liani, R., Ciotti, S., Birkeland, K. I., Gulseth, H. L., Castelnuovo, A. F. D., Cipollone, F., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01469-w · Cited by 19 · see citing works
New Insights into the Use of Liraglutide—Impact on Cardiovascular Risk and Microvascular Outcomes
Wronka, M., Krzemińska, J., Młynarska, E., Rysz, J., & Franczyk, B. (2023) · Biomedicines · doi:10.3390/biomedicines11041159 · Cited by 19 · see citing works
Anti-Arrhythmic Effects of Heart Failure Guideline-Directed Medical Therapy and Their Role in the Prevention of Sudden Cardiac Death: From Beta-Blockers to Sodium-Glucose Cotransporter 2 Inhibitors and Beyond
Zaher, W., Rocca, D. G. D., Pannone, L., Bovéda, S., de Asmundis, C., Chierchia, G., & Sorgente, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051316 · Cited by 18 · see citing works
Diastolic Cardiac Function Improvement by Liraglutide Is Mainly Body Weight Reduction Dependent but Independently Contributes to B-Type Natriuretic Peptide Reduction in Patients with Type 2 Diabetes with Preserved Ejection Fraction
Yagi, K., Imamura, T., Tada, H., Chujo, D., Liu, J., Shima, Y., Ohbatake, A., Miyamoto, Y., Okazaki, S., Ito, N., et al. (2021) · Journal of Diabetes Research · doi:10.1155/2021/8838026 · Cited by 18 · see citing works
Liraglutide Ameliorates Cerebral Ischemia in Mice via Antipyroptotic Pathways
Yang, L., Cheng, J., Shi, G., Zhang, C., Du, Y., Chen, L., Qiao, H., Chen, R., & Zhang, X. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03574-4 · Cited by 18 · see citing works
Glimepiride use is associated with reduced cardiovascular mortality in patients with type 2 diabetes and chronic heart failure: a prospective cohort study
He, W., Yuan, G., Han, Y., Yan, Y., Li, G., Zhao, C., Shen, J., Jiang, X., Chen, C., Ni, L., et al. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac312 · Cited by 18 · see citing works
Cardioprotective effects of liraglutide pretreatment on isoprenaline-induced myocardial injury in rats
Bajić, Z., Šobot, T., Uletilović, S., Mandić-Kovačević, N., Cvjetković, T., Maličević, U., Đukanović, Đ., Duran, M., Vesić, N., Avram, S., et al. (2023) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2022-0534 · Cited by 18 · see citing works
Heart Failure in Type 1 Diabetes: A Complication of Concern? A Narrative Review
Gómez‐Pérez, A. M., Damas-Fuentes, M., Cornejo-Pareja, I. M., & Tinahones, F. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194497 · Cited by 18 · see citing works
Research status and trends of the diabetic cardiomyopathy in the past 10 years (2012–2021): A bibliometric analysis
Wang, S., Tian, C., Gao, Z., Zhang, B., & Zhao, L. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1018841 · Cited by 17 · see citing works
The potential of glucagon-like peptide-1 receptor agonists in heart failure
Kreiner, F. F., Hovingh, G. K., & von Scholten, B. J. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.983961 · Cited by 16 · see citing works
A meta-analysis evaluating indirectly GLP-1 receptor agonists and arrhythmias in patients with type 2 diabetes and myocardial infarction
Liu, Z., Bian, N., Wu, S., Fan, Y., Li, H., Yu, J. Y., Guo, J., & Chen, D. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1019120 · Cited by 17 · see citing works
Comparison of Glucose Control by Added Liraglutide to Only Insulin Infusion in Diabetic Patient Undergoing Cardiac Surgery
Sindhvananda, W., Poopuangpairoj, W., Jaiprasat, T., & Ongcharit, P. (2023) · Annals of Cardiac Anaesthesia · doi:10.4103/aca.aca_214_20 · Cited by 16 · see citing works
Improvement of Left Ventricular Global Longitudinal Strain after 6-Month Therapy with GLP-1RAs Semaglutide and Dulaglutide in Type 2 Diabetes Mellitus: A Pilot Study
Basile, P., Guaricci, A. I., Piazzolla, G., Volpe, S., Vozza, A., Benedetto, M., Carella, M. C., Santoro, D., Monitillo, F., Baggiano, A., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041586 · Cited by 16 · see citing works
Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonance
Cersosimo, A., Salerno, N., Sabatino, J., Scatteia, A., Bisaccia, G., Rosa, S. D., Dellegrottaglie, S., Bucciarelli‐Ducci, C., Torella, D., & Leo, I. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02181-7 · Cited by 16 · see citing works
Comparative evaluation of metformin and liraglutide cardioprotective effect in rats with impaired glucose tolerance
Симаненкова, А. В., Минасян, С. М., Каронова, Т. Л., Vlasov, T. D., Тимкина, Н. В., Shpilevaya, O., Константиновна, Х. А., Shimshilashvili, A., Тимофеева, В. А., Samsonov, D., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-86132-2 · Cited by 16 · see citing works
Current challenges in the treatment of cardiac fibrosis: Recent insights into the sex‐specific differences of glucose‐lowering therapies on the diabetic heart: IUPHAR Review 33
Sharma, A., Blasio, M. J. D., & Ritchie, R. H. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15820 · Cited by 16 · see citing works
The role and therapeutic potential of macrophages in the pathogenesis of diabetic cardiomyopathy
Zhang, S., Zhu, X., Chen, Y., Wen, Z., Shi, P., & Ni, Q. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1393392 · Cited by 15 · see citing works
Clinical Update in Heart Failure with Preserved Ejection Fraction
Krittanawong, C., Britt, W., Rizwan, A. M., Siddiqui, R., Khawaja, M., Khan, R., Joolharzadeh, P., Newman, N. A., Rivera, M. R. R., & Tang, W. H. W. (2024) · Current Heart Failure Reports · doi:10.1007/s11897-024-00679-5 · Cited by 17 · see citing works
Incidence of idiopathic cardiomyopathy in patients with type 2 diabetes in Taiwan: age, sex, and urbanization status-stratified analysis
Chen, H.-F., Chang, Y., Lo, H.-J. L., Isfandiari, M. A., Martini, S., Hou, W., & Li, C. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01144-y · Cited by 14 · see citing works
Metabolic improvement with short‐term, glucagon‐like peptide‐1 receptor agonist treatment does not improve cardiac diastolic dysfunction in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial
Bojer, A. S., Sørensen, M. H., Bjerre, J., Gæde, P., Vejlstrup, N. G., & Madsen, P. L. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14480 · Cited by 14 · see citing works
The Role of Mitochondria in Metabolic Syndrome–Associated Cardiomyopathy
Li, J., Li, J., Chen, Y., Hu, W., Gong, X., Qiu, H., Chen, H., Xin, Y., & Li, H. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/9196232 · Cited by 16 · see citing works
Altered high‐density lipoprotein composition is associated with risk for complications in type 2 diabetes mellitus in South Asian descendants: A cross‐sectional, case‐control study on lipoprotein subclass profiling
Yuan, L., Li‐Gao, R., Verhoeven, A., van Eyk, H. J., Bizino, M. B., Rensen, P. C. N., Giera, M. A., Jazet, I. M., Lamb, H. J., Rabelink, T. J., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15118 · Cited by 13 · see citing works
Intensive Lifestyle Intervention, Cardiac Biomarkers, and Cardiovascular Outcomes in Diabetes
Patel, K. V., Chunawala, Z. S., Verma, S., Segar, M. W., Garcia, K. R., Ndumele, C. E., Wang, T. J., Januzzi, J. L., Bayés‐Genís, A., Butler, J., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.11.004 · Cited by 14 · see citing works
Cardioprotective properties of glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients: A systematic review
Widiarti, W., Sukmajaya, A. C., Nugraha, D., & Alkaff, F. F. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.04.005 · Cited by 13 · see citing works
Differences in Inflammatory Pathways Between Dutch South Asians vs Dutch Europids With Type 2 Diabetes
Straat, M. E., Martínez‐Téllez, B., van Eyk, H. J., Bizino, M. B., van Veen, S., Vianello, E., Stienstra, R., Ottenhoff, T. H. M., Lamb, H. J., Smit, J. W. A., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac598 · Cited by 12 · see citing works
Type 2 diabetes and cardiovascular disease: risk reduction and early intervention
Hinnen, D., Kruger, D. F., & MAGWIRE, M. L. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2126235 · Cited by 13 · see citing works
Efficacy and Safety of Tirzepatide Compared with GLP-1 RAs in Patients with Type 2 Diabetes Treated with Basal Insulin: A Network Meta-analysis
Osumili, B., Sapin, H., Yang, Z., Ranta, K., Paik, J. S., & Blüher, M. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01728-5 · Cited by 12 · see citing works
HFpEF as the predominant and underrecognized heart failure phenotype in type 2 diabetes: evidence from the DIABET-IC study
Gil, P., Gimeno-Orna, J. A., Padial, L. R., Muñiz, J., Barrios, V., Anguita, M. P., & Pérez, A. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02995-z · Cited by 11 · see citing works
The effect of exenatide (a GLP-1 analogue) and sitagliptin (a DPP-4 inhibitor) on asymmetric dimethylarginine (ADMA) metabolism and selected biomarkers of cardiac fibrosis in rats with fructose-induced metabolic syndrome
Wójcicka, G., Pradiuch, A., Fornal, E., Stachniuk, A., Korolczuk, A., Marzec‐Kotarska, B., Nikolaichuk, H., Czechowska, G., Kozub, A., Trzpil, A., et al. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115637 · Cited by 9 · see citing works
Transient receptor potential vanilloid type 1: cardioprotective effects in diabetic models
Bao, J., Gao, Z., Hu, Y., Ye, L., & Wang, L. (2023) · Channels · doi:10.1080/19336950.2023.2281743 · Cited by 9 · see citing works
Subclinical HMOD in Hypertension: Left Ventricular Diastolic Dysfunction
Bertacchini, F., Rosei, C. A., Buso, G., Cappellini, S., Stassaldi, D., Aggiusti, C., Salvetti, M., Paini, A., Ciuceis, C. D., & Muiesan, M. L. (2022) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-022-00548-z · Cited by 9 · see citing works
Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis
Huang, Y., Xu, X.-Z., Liu, J., Wang, P.-Y., Wang, X., Feng, H., Liu, C., & Han, X. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03324-6 · Cited by 8 · see citing works
Efficacy of liraglutide on glycemic endpoints in people of Western European and South Asian descent with T2DM using multiple daily insulin injections: results of the MAGNA VICTORIA studies
Bizino, M. B., Jazet, I. M., van Eyk, H. J., Rensen, P. C. N., Geelhoed-Duijvestijn, P. H. L. M., Kharagjitsingh, A. V., Paiman, E. H. M., Smit, J. W. A., & Lamb, H. J. (2021) · Acta Diabetologica · doi:10.1007/s00592-020-01635-0 · Cited by 8 · see citing works
MR Assessed Changes of Renal Sinus Fat in Response to Glucose Regulation in West European and South Asian Patients With Type 2 Diabetes
Lin, L., Dekkers, I. A., Tao, Q., Paiman, E. H. M., Bizino, M. B., Jazet, I. M., & Lamb, H. J. (2023) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.29174 · Cited by 8 · see citing works
Pharmacologic Treatment of Pulmonary Hypertension Due to Heart Failure with Preserved Ejection Fraction: Are There More Arrows on Our Bow?
Masarone, D., Valente, F., Verrengia, M., Contaldi, C., Palma, V. D., Falco, L., Catapano, D., & di Lorenzo, E. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226867 · Cited by 7 · see citing works
Therapeutic Potential of GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction (HFpEF) in Obese Patients
Patel, R., Kokori, E., Olatunji, G. D., Adejumo, F. A., Ukah, J. D., Babalola, A. E., Ndakotsu, A., Abraham, I. C., & Aderinto, N. (2025) · Current Heart Failure Reports · doi:10.1007/s11897-025-00704-1 · Cited by 7 · see citing works
Hypoglycemic Drugs in Patients with Diabetes Mellitus and Heart Failure: A Narrative Review
Nikolaidou, A., Ventoulis, I., Karakoulidis, G., Anastasiou, V., Daios, S., Papadopoulos, S.-F., Didagelos, M., Parissis, J., Karamitsos, T. D., Kotsa, K., et al. (2024) · Medicina · doi:10.3390/medicina60060912 · Cited by 8 · see citing works
Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials
Xia, W., Yu, H., Lei, X., & Wen, P. (2024) · Medicine · doi:10.1097/md.0000000000037432 · Cited by 7 · see citing works
Hepatic triglyceride content does not affect circulating CETP: lessons from a liraglutide intervention trial and a population-based cohort
van Eyk, H. J., Blauw, L. L., Bizino, M. B., Wang, Y., van Dijk, K. W., de Mutsert, R., Smit, J. W. A., Lamb, H. J., Jazet, I. M., & Rensen, P. C. N. (2019) · Scientific Reports · doi:10.1038/s41598-019-45593-2 · Cited by 7 · see citing works
Critical Appraisal of Pharmaceutical Therapy in Diabetic Cardiomyopathy—Challenges and Prospectives
Khattab, E., Kyriakou, M., Leonidou, E., Sokratous, S., Mouzarou, A., Myrianthefs, M. M., & Kadoglou, N. P. E. (2025) · Pharmaceuticals · doi:10.3390/ph18010134 · Cited by 7 · see citing works
Ethnic Disparities in Lipid Metabolism and Clinical Outcomes between Dutch South Asians and Dutch White Caucasians with Type 2 Diabetes Mellitus
Yuan, L., Verhoeven, A., Blomberg, N., van Eyk, H. J., Bizino, M. B., Rensen, P. C. N., Jazet, I. M., Lamb, H. J., Rabelink, T. J., Giera, M. A., et al. (2024) · Metabolites · doi:10.3390/metabo14010033 · Cited by 6 · see citing works
Effect of glucose regulation on renal parenchyma and sinus fat volume in patients with type 2 diabetes
Lin, L., Dekkers, I. A., Tao, Q., Paiman, E. H. M., Bizino, M. B., Jazet, I. M., & Lamb, H. J. (2022) · Diabetes & Metabolism · doi:10.1016/j.diabet.2022.101408 · Cited by 6 · see citing works
Mechanisms of GLP-1 Receptor Agonists in HFpEF: Exploring Weight-Dependent and Independent Drivers of Therapeutic Benefit
Thomas, J., Dagan, M., Wang, B. H., Gutman, S., & Kaye, D. M. (2026) · Circulation Heart Failure · doi:10.1161/circheartfailure.125.013279 · Cited by 6 · see citing works

Randomised Placebo Controlled Trial to Assess the Effect of Liraglutide on Cardiac Function in Type 2 Diabetes Mellitus PatientsPreprint
Bizino, M. B., Jazet, I. M., Westenberg, J. J. M., van Eyk, H. J., Paiman, E. H. M., Smit, J. W. A., Lamb, H. J., & Roos, A. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3204722
Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials
Xia, W., Yu, H., Lei, X., & Wen, P. (2024) · Medicine · doi:10.1097/md.0000000000037432 · Cited by 7 · see citing works
Effect of Liraglutide on Cardiovascular Function and Myocardial Tissue Characteristics in Type 2 Diabetes Patients of South Asian Descent Living in the Netherlands: A Double‐Blind, Randomized, Placebo‐Controlled Trial
Paiman, E. H. M., van Eyk, H. J., van Aalst, M., Bizino, M. B., van der Geest, R. J., Westenberg, J. J. M., Geelhoed-Duijvestijn, P. H. L. M., Kharagjitsingh, A. V., Rensen, P. C. N., Smit, J. W. A., et al. (2019) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.27009 · Cited by 42 · see citing works
Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study
Kumarathurai, P., Sajadieh, A., Anholm, C., Kristiansen, O. P., Haugaard, S. B., & Nielsen, O. W. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01205-2 · Cited by 31 · see citing works
Effect of Liraglutide on Cardiac Function in Individuals With Type 2 Diabetes: A Meta-Analysis
Haroon, H., Kumari, A., Lal, B., Kumari, A., Kumar, J., Khreis, K., Sheikh, M., & Amin, A. (2023) · Cureus · doi:10.7759/cureus.42651 · Cited by 4 · see citing works

Authors: Bizino, M. B., Jazet, I. M., Westenberg, J. J. M., van Eyk, H. J., Paiman, E. H. M., Smit, J. W. A., & Lamb, H. J.
Affiliations: Leiden University Medical Center (NL)
Corresponding author: Bizino, Maurice B.
ORCID: Bizino, Maurice B.
Jazet, Ingrid M.
Westenberg, Jos J. M.
Paiman, Elisabeth H. M.
Venue: Cardiovascular Diabetology
Publisher: Springer Science and Business Media LLC
Published: 2019-04-30
Volume: 18
Issue: 1
Pages: 55-55
ISSN: 1475-2840 (ISSN-L)
DOI: 10.1186/s12933-019-0857-6
PMC: PMC6492440
OpenAlex: W2946264273
Cited by: 137
References: 42
Citations by year: 2026: 8 · 2025: 12 · 2024: 21 · 2023: 20 · 2022: 26 · 2021: 18 · 2020: 25 · 2019: 7
FWCI: 15.41
Type: journal article
Language: en
Update notices: correction (2019-08-09)
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0 (tdm)
creativecommons.org/licenses/by/4.0 (vor)
Locations: Cardiovascular Diabetology (publishedVersion, cc-by)
Europe PMC (PubMed Central) (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
Radboud Repository (Radboud University) (submittedVersion, other-oa)
Data Archiving and Networked Services (DANS) (submittedVersion)
Leiden Repository (Leiden University) (submittedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Radboud Repository (Radboud University) (submittedVersion)
Funders: Novo Nordisk (NA)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords: liraglutide, type 2 diabetes, diabetic cardiomyopathy, left ventricular diastolic function, left ventricular filling pressure, left ventricular systolic function, cardiac magnetic resonance, GLP-1 receptor agonists, cardioprotection, stroke volume, ejection fraction, cardiac unloading, cardiovascular risk reduction
MeSH terms: Liraglutide, Adolescent, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Humans, Hypoglycemic Agents, Magnetic Resonance Imaging, Male, Middle Aged, Netherlands, Stroke Volume, Time Factors, Biomarkers, Ventricular Function, Left, Treatment Outcome, Ventricular Pressure, Ventricular Dysfunction, Left, Recovery of Function, Young Adult, Diabetic Cardiomyopathies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: Randomized placebo-controlled trial

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks